Shorter Duration of Antibiotics in Low-Risk Febrile Neutropenia in Children with Malignancy
- PMID: 33411261
- DOI: 10.1007/s12098-020-03654-9
Shorter Duration of Antibiotics in Low-Risk Febrile Neutropenia in Children with Malignancy
Comment on
-
Early Discontinuation versus Continuation of Antimicrobial Therapy in Low Risk Pediatric Cancer Patients with Febrile Neutropenia, Before Recovery of Counts: A Randomized Controlled Trial (DALFEN Study).Indian J Pediatr. 2021 Mar;88(3):240-245. doi: 10.1007/s12098-020-03377-x. Epub 2020 Jun 15. Indian J Pediatr. 2021. PMID: 32537711 Clinical Trial.
References
-
- Oberoi S, Suthar R, Bansal D, Marwaha RK. Febrile neutropenia: outline of management. Indian J Pediatr. 2013;80(2):138–43. - DOI
-
- Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52(4):e56–93. - DOI
-
- Alexander SW, Wade KC, Hibberd PL, Parsons SK. Evaluation of risk prediction criteria for episodes of febrile neutropenia in children with cancer. J Pediatr Hematol Oncol. 2002;24(1):38–42. - DOI
-
- Lehrnbecher T, Robinson P, Fisher B, et al. Guideline for the management of fever and neutropenia in children with cancer and hematopoietic stem-cell transplantation recipients: 2017 update. J Clin Oncol. 2017;35(18):2082–94. - DOI
-
- Kumar A, Biswas B, Chopra A, Kapil A, Vishnubhatla S, Bakhshi S. Early discontinuation versus continuation of antimicrobial therapy in low risk pediatric cancer patients with febrile neutropenia, before recovery of counts: a randomized controlled trial (DALFEN study). Indian J Pediatr. 2020. https://doi.org/10.1007/s12098-020-03377-x .
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical